Gurdane Bhutani
Co-founder & Managing Partner @ MBX Capital
New York, United States
Gurdane Bhutani is a seed investor at MBX Capital in New York focused on Health Care and Biotechnology. Gurdane Singh Bhutani is the Managing Partner, MBX Capital. He attended Yale University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Gurdane Bhutani invests in
Stages Gurdane Bhutani invests in
Countries Gurdane Bhutani invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Apps 1 (25%)
- Fitness 1 (25%)
- Wellness 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $7.2M / Series A / Nov 10, 2022 | ||
| Freedom Biosciences is a biotechnology platform developing next-generation psychedelic therapeutics. | $10.5M / Seed / Aug 23, 2022 | ||
| Physical therapy is powerful—for developing strength, managing emerging conditions, or recovering from surgery. But it’s challenging for physical therapy to make a significant clinical impact because therapists and patients are worn out.Traditional physical therapy leaves more than 50% of therapists suffering from work-related pain and 70% ofpatients failing to complete their course of care. On both sides of the therapy table, people need better support.At Luna, they’re designing a practice that gives therapists and patients the independence, control, and motivation they need to feel meaningful relief. | Series B / Jun 02, 2022 | ||
| Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $10.7M / Series A / Oct 20, 2021 |
Co-Investors
About MBX Capital
MBX Capital is a venture capital partnership investing in early-stage healthcare, life sciences, and environmental health companies
MBX Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elizabeth Burstein
Venture Partner
|
|||
|
Gurdane Bhutani
Co-founder & Managing Partner
|
|||
|
Martin Gargaros
Director
|
|||
Puneet Sapra
Venture Partner
|
|||
Zeshan Muhammedi
Co-founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Gurdane Bhutani invest in?
Gurdane Bhutani invests primarily in Health Care, Biotechnology and Apps startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gurdane Bhutani?
Public channels for Gurdane Bhutani include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gurdane Bhutani last invest?
The most recent investment recorded for Gurdane Bhutani closed in Nov 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
